FindTrial
Sign In

The predictive value of Anti-PCX and regulatory T cell for therapeutic effect of traditional chinese medicine on IMN patients

The predictive value of Anti-PCX and regulatory T cell for therapeutic effect of traditional chinese medicine on IMN patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-16009632
Enrollment
Unknown
Registered
2016-10-27
Start date
2016-11-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Membranous nephropathy

Interventions

IMN:Traditional Chinese Medicine
Non-IMN:Traditional Chinese Medicine

Sponsors

Longhua hospital affiliated to Shanghai university of traditional Chinese medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 yrs old, male or female; 2. Membranous nephropathy proved by renal pathology; 3. Eliminate secondary membranous nephropathy (HBV, HCV, malignant tumor, SLE, autoimmune disease or drug associated MN).

Exclusion criteria

Exclusion criteria: 1. Patients without renal biopsy; 2. Pregnant or breast-feeding women; 3. Complicated with other sever organic and functional disorder; 4. Disable patients; 5. The patients have been participating in other researches.

Design outcomes

Primary

MeasureTime frame
serum anti-PLA2R antibodies;THSD7A;SOD2;a ENO;AR;regulatory T cell;—

Countries

China

Contacts

Public ContactWang Lin

Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine

happytlynn@163.com+86 13564567336

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026